Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Silo Pharma Inc (NQ: SILO ) 2.111 -0.359 (-14.54%) Streaming Delayed Price Updated: 1:19 PM EDT, Jul 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Silo Pharma Inc < Previous 1 2 3 4 5 Next > BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) to Participate in Upcoming H.C. Wainwright Annual Global Investment Conference July 26, 2024 Via Investor Brand Network Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference July 26, 2024 From Silo Pharma, Inc. Via GlobeNewswire Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules July 22, 2024 From Silo Pharma, Inc. Via GlobeNewswire BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Enters into $2.1M Registered Direct Offering July 19, 2024 Via Investor Brand Network Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules July 19, 2024 From Silo Pharma, Inc. Via GlobeNewswire BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Enters Device and CMC Development Master Plan to Support IND-Enabling Study of SPC-15 July 18, 2024 Via Investor Brand Network Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15 July 18, 2024 From Silo Pharma, Inc. Via GlobeNewswire InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Exclusive Global License to Develop, Manufacture, Commercialize Alzheimer Drug July 16, 2024 Via Investor Brand Network Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic July 16, 2024 From Silo Pharma, Inc. Via GlobeNewswire InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters License Agreement with Columbia University for Lead Candidate Targeting PTSD, Stress-Induced Anxiety Disorders July 08, 2024 Via Investor Brand Network Exposures Product Safety Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders July 08, 2024 From Silo Pharma, Inc. Via GlobeNewswire InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Collaborates with CRO Partner to Advance SPC-15 for PTSD June 26, 2024 Via Investor Brand Network Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety June 26, 2024 From Silo Pharma, Inc. Via GlobeNewswire PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes on $2M Registered Direct Offering, Provides Update on SP-26 Ketamine Implant Therapeutic June 07, 2024 Via Investor Brand Network Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia June 07, 2024 From Silo Pharma, Inc. Via GlobeNewswire Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules June 06, 2024 From Silo Pharma, Inc. Via GlobeNewswire InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Registered Direct Offering Estimated to Reach $2M June 05, 2024 Via Investor Brand Network Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules June 05, 2024 From Silo Pharma, Inc. Via GlobeNewswire InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Pre-IND Submission for Proprietary Treatment for PTSD, Anxiety June 04, 2024 Via Investor Brand Network Exposures Product Safety Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety June 04, 2024 From Silo Pharma, Inc. Via GlobeNewswire Silo Pharma’s (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors June 04, 2024 Via AB Newswire Exposures Product Safety PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares ‘Significant Development’ in Depression Study Showing Potential to Extend Remission Period, Prevent Relapse May 21, 2024 Via Investor Brand Network Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention May 21, 2024 From Silo Pharma, Inc. Via GlobeNewswire BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Announces Participation in FDA Event Exploring Emerging Therapeutic Interest in Ketamine May 14, 2024 Via Investor Brand Network Exposures Product Safety Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine May 14, 2024 Silo’s SP-26 currently in development utilizes ketamine as primary therapeutic agent From Silo Pharma, Inc. Via GlobeNewswire InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares Positive Results for PTSD Treatment April 23, 2024 Via Investor Brand Network Silo Pharma Announces Positive Results for Intranasal PTSD Treatment April 23, 2024 From Silo Pharma, Inc. Via GlobeNewswire InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Plans for Exclusive Licensing of Novel Therapeutic for Alzheimer’s Disease April 10, 2024 Via Investor Brand Network Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic April 10, 2024 From Silo Pharma, Inc. Via GlobeNewswire InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Exercises Option for Exclusive License Agreement for SPC-15 March 20, 2024 Via Investor Brand Network Exposures Product Safety < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
